27626099|t|Peptide -Mediated Interference of PB2 - eIF4G1 Interaction Inhibits Influenza A Viruses ' Replication in Vitro and in Vivo
27626099|a|Influenza viruses are obligate parasites that hijack the host cellular system. Previous results have shown that the influenza virus PB2 subunit confers a dependence of host eukaryotic translation initiation factor 4-γ 1 (eIF4G1) for viral mRNA translation. Here, we demonstrated that peptide -mediated interference of the PB2 - eIF4G1 interaction inhibited virus replication in vitro and in vivo. Remarkably, intranasal administration of the peptide provided 100% protection against lethal challenges of influenza A viruses in BALB/c mice, including H1N1, H5N1, and H7N9 influenza virus subtypes. Mapping of the PB2 protein indicated that the eIF4G1 binding sites resided within the PB2 cap - binding domain. Virtual docking analysis suggested that the inhibitory peptide associated with the conserved amino acid residues that were essential to PB2 cap-binding activity. Overall, our results identified the PB2 - eIF4G1 interactive site as a druggable target for influenza therapeutics.
27626099	0	7	Peptide	T103	UMLS:C0030956
27626099	34	37	PB2	T103	UMLS:C0753209
27626099	40	46	eIF4G1	T103	UMLS:C1505487
27626099	47	58	Interaction	T038	UMLS:C0872079
27626099	68	87	Influenza A Viruses	T005	UMLS:C0029347
27626099	90	101	Replication	T038	UMLS:C0042774
27626099	123	140	Influenza viruses	T005	UMLS:C0029341
27626099	145	163	obligate parasites	T204	UMLS:C0562628
27626099	169	200	hijack the host cellular system	T038	UMLS:C1154502
27626099	239	258	influenza virus PB2	T103	UMLS:C1611366
27626099	291	342	host eukaryotic translation initiation factor 4-γ 1	T103	UMLS:C1505487
27626099	344	350	eIF4G1	T103	UMLS:C1505487
27626099	356	378	viral mRNA translation	T038	UMLS:C1154505
27626099	407	414	peptide	T103	UMLS:C0030956
27626099	445	448	PB2	T103	UMLS:C0753209
27626099	451	457	eIF4G1	T103	UMLS:C1505487
27626099	458	469	interaction	T038	UMLS:C0872079
27626099	480	497	virus replication	T038	UMLS:C0042774
27626099	532	557	intranasal administration	T058	UMLS:C0001560
27626099	565	572	peptide	T103	UMLS:C0030956
27626099	606	612	lethal	T033	UMLS:C3151529
27626099	613	623	challenges	T058	UMLS:C0805586
27626099	627	646	influenza A viruses	T005	UMLS:C0029347
27626099	650	661	BALB/c mice	T204	UMLS:C0025919
27626099	673	677	H1N1	T005	UMLS:C1615607
27626099	679	683	H5N1	T005	UMLS:C1613950
27626099	689	718	H7N9 influenza virus subtypes	T005	UMLS:C3658219
27626099	720	727	Mapping	T062	UMLS:C0949728
27626099	735	746	PB2 protein	T103	UMLS:C0753209
27626099	766	772	eIF4G1	T103	UMLS:C1505487
27626099	773	786	binding sites	T103	UMLS:C0005456
27626099	806	813	PB2 cap	T103	UMLS:C0753209
27626099	816	830	binding domain	T038	UMLS:C1149343
27626099	832	856	Virtual docking analysis	T170	UMLS:C3494274
27626099	887	894	peptide	T103	UMLS:C0030956
27626099	925	944	amino acid residues	T103	UMLS:C0002520
27626099	968	971	PB2	T103	UMLS:C0753209
27626099	972	992	cap-binding activity	T058	UMLS:C0201711
27626099	1030	1033	PB2	T103	UMLS:C0753209
27626099	1036	1042	eIF4G1	T103	UMLS:C1505487
27626099	1043	1059	interactive site	T103	UMLS:C0005456
27626099	1065	1074	druggable	T103	UMLS:C1254351
27626099	1086	1095	influenza	T038	UMLS:C0021400
27626099	1096	1108	therapeutics	T058	UMLS:C0087111